2 results match your criteria: "Ospedale G. Bosco e Universita' di Torino[Affiliation]"
[Hepatitis virus-related nephropathies].
G Ital Nefrol
August 2015
Centro di Ricerche di Immunopatologia e Documentazione su Malattie Rare (CMID), Dipartimento di Malattie Rare, Immunologiche, Ematologiche e Immunoematologiche, Ospedale G. Bosco e Universita' di Torino, Torino - Italy.
Article Synopsis
- Hepatitis B virus (HBV) can cause extrahepatic issues like reactive arthritis, vasculitis, and different types of glomerulonephritis, but there are no specific histological patterns linked to Hepatitis D virus (HDV) infections.
- For HBV-related kidney problems, antiviral treatment is the main approach; corticosteroids are generally ineffective (except for panarteritis nodosa), and immunosuppressants risk worsening HBV.
- Hepatitis C virus (HCV) can induce cryoglobulinemic glomerulonephritis, and its treatment may involve a mix of immunomodulatory agents and antiviral therapy.
[The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
G Ital Nefrol
January 2012
Centro di Ricerche di Immunopatologia e Documentazione su Malattie Rare, Ospedale G. Bosco e Universita di Torino, Torino, Italy.
A considerable minority of patients with ANCA-associated small-vessel vasculitis are refractory to conventional therapy or experience dose-limiting side effects. Novel therapeutic approaches include rituximab, a genetically engineered chimeric murine-human monoclonal antibody that binds to CD20, which is expressed on human B cells. It was approved in 1997 for the treatment of CD20-positive B-cell non-Hodgkin lymphoma and in 2006 for the treatment of rheumatoid arthritis.
View Article and Find Full Text PDF